Project Details
Description
ABSTRACT
T-cell large granular lymphocytic leukemia (T-LGLL) is an incurable, underdiagnosed proliferation of clonal CD8+
cytotoxic T-lymphocytes that results in severe neutropenia and anemia, with resultant recurring infections,
transfusion dependence, and death. There are no FDA-approved therapies for T-LGLL, and current immune-
suppressive based therapies have marginal efficacy. Even if a response is attained with current therapies,
patients shift between immune-suppressive agents, are subject to the adverse effects of these drugs, and for
those with any effect, indefinite therapy is required. Urgent investigation into the pathogenesis of T-LGLL and
development of rational, targeted therapies are needed. T-LGLL is a cytokine-dependent disease, driven by
interleukin-15 (IL-15) which has been identified as the ‘master switch’ crucial to induce and potentiate T-LGLL.
IL-15 induces pathogenesis in T-LGLL through up-regulation of STAT3, with resultant decrease in Fas/Fas-
Ligand mediated apoptosis with resultant T-LGLL proliferation and cytopenias. We evaluated BNZ-1, a
γc-inhibiting peptide that blocks IL-15, in patients with T-LGLL in only the second major, multicenter trial
completed in T-LGLL. Clinical responses were observed in 20% of patients, but in vivo data revealed that nearly
all patients had dramatic apoptosis of T-LGLL cells 24 hours post-BNZ-1, though apoptosis persisted only in
responding patients at day 29. These results (in revision, Blood), provide in vivo proof that BNZ-1 induces T-
LGLL cell apoptosis, and that T-LGLL cells are dependent on IL-15 in vivo in patients. To evaluate the
mechanisms of resistance to IL-15 deprivation induced cell death, we performed single-cell RNA sequencing
(scRNAseq) on samples from a non-responder. We identified the emergence of unique T-LGLL sub-populations
on day 29, with corresponding up-regulation of anti-apoptotic pathways PI3K and NF-kB; implicating up-
regulation of these alternate pathways in T-LGLL as key mechanisms of resistance of T-LGLL to IL-15
deprivation. Yet, validation in a larger sample set is needed to confirm these findings and identify therapeutic
targets. To address these translational and clinical gaps, we will perform scRNAseq and single-cell T-cell
receptor sequencing (scTCRseq) on remaining clinically annotated samples from 3 responders and 3 non-
responders from the BNZ-1 trial to test our hypothesis that resistance to IL-15 deprivation with BNZ-1 is caused
by expansion of resistant T-LGLL populations with upregulation of anti-apoptotic pathways (e.g. NF-kB, PI3K).
In Aim 1, we will perform scRNAseq at serial timepoints (baseline, 24 hours post-BNZ-1, 29 days post BNZ-1),
to identify key anti-apoptotic pathways, genes, and therapeutic targets in resistant populations. In Aim 2, we will
apply scTCRseq to evaluate T-LGLL clonal populations (clonotypes), and determine the impact of IL-15
deprivation on gene expression and anti-apoptotic pathways in these groups. Upon completion, we will gain
crucial mechanistic insights on the critical genes and anti-apoptotic pathways in T-LGLL that lead to resistance
to IL-15 deprivation and identify therapeutic targets for a future NCI R01 proposal and BNZ-1 combinatorial trial.
Status | Active |
---|---|
Effective start/end date | 01/1/24 → 12/31/24 |
Funding
- National Cancer Institute: $78,750.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.